大葉大學圖書館 |

登入

回首頁 到查詢結果 [ author_sort:"chow, shein-chung, (1955-)" ]

Controversial statistical issues in ...

Chow, Shein-Chung, (1955-)

Controversial statistical issues in clinical trials[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	615.5072/4
書名/作者:	Controversial statistical issues in clinical trials/ Shein-Chung Chow.
作者:	Chow, Shein-Chung,
出版者:	Boca Raton : : CRC Press,, c2011.
面頁冊數:	1 online resource (xix, 591 p.) : : ill.
標題:	Drugs - Testing.
標題:	Drug development.
標題:	Clinical trials.
標題:	Clinical Trials as Topic.
標題:	Drug Evaluation, Preclinical.
標題:	Data Interpretation, Statistical.
ISBN:	9781439849620 (electronic bk.)
書目註:	Includes bibliographical references (p. 553-575) and index.
摘要、提要註:	"Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "--
電子資源:	http://www.crcnetbase.com/isbn/9781439849620

Controversial statistical issues in clinical trials[electronic resource] /
Chow, Shein-Chung,1955-

Controversial statistical issues in clinical trials[electronic resource] /Shein-Chung Chow. - Boca Raton :CRC Press,c2011. - 1 online resource (xix, 591 p.) :ill. - Chapman & Hall/CRC biostatistics series. - Chapman & Hall/CRC biostatistics series..

Includes bibliographical references (p. 553-575) and index.

"Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "--

ISBN: 9781439849620 (electronic bk.)

LCCN: 2011024204Subjects--Topical Terms:

431364
Drugs
--Testing.

LC Class. No.: RM301.27 / .C475 2011

Dewey Class. No.: 615.5072/4

National Library of Medicine Call No.: QV 771

Controversial statistical issues in clinical trials[electronic resource] /
LDR:02335cam a2200277 a 4500 001 457064
005 20150206143227.0
006 m o d
007 cr |n|---|||||
008 161227s2011 flua ob 001 0 eng
010 $a 2011024204
020 $a 9781439849620 (electronic bk.)
020 $z 9781439849613 (hardback)
035 $a (DNLM)101562559
035 $a 16827822
040 $a DNLM/DLC $c DLC $d DLC
050 0 0 $a RM301.27 $b .C475 2011
060 1 0 $a QV 771
082 0 0 $a 615.5072/4 $2 23
100 1 $a Chow, Shein-Chung, $d 1955- $3 488622
245 1 0 $a Controversial statistical issues in clinical trials $h [electronic resource] / $c Shein-Chung Chow.
260 $a Boca Raton : $b CRC Press, $c c2011.
300 $a 1 online resource (xix, 591 p.) : $b ill.
490 1 $a Chapman & Hall/CRC biostatistics series
504 $a Includes bibliographical references (p. 553-575) and index.
520 $a "Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "-- $c Provided by publisher.
588 $a Description based on print version record.
650 0 $a Drugs $x Testing. $3 431364
650 0 $a Drug development. $3 339189
650 0 $a Clinical trials. $3 339385
650 1 2 $a Clinical Trials as Topic. $3 438608
650 1 2 $a Drug Evaluation, Preclinical. $3 431418
650 2 2 $a Data Interpretation, Statistical. $3 342902
830 0 $a Chapman & Hall/CRC biostatistics series. $3 559311
856 4 0 $u http://www.crcnetbase.com/isbn/9781439849620

筆 0 讀者評論

多媒體

多媒體檔案
http://www.crcnetbase.com/isbn/9781439849620

評論

新增評論分享你的心得

Export

取書館別